] i ) has been proposed by Dr. Okamoto and colleagues. The origin of this model dates back to 1993 when the first report [1] and accompanying editorial in Science [2] depicted it as a significant advancement in our understanding of Ca 2+ -signalling in these cells. In this model, cADPR releases Ca 2+ from endoplasmic reticulum (ER) by activating the ryanodine receptor (Ry) and Ca 2+ released from ER plays an important role in stimulating insulin secretion. Furthermore Dr. Okamoto maintains that beta cells do not possess a mechanism for Ca 2+ release by inositol(1,4,5)trisphosphate (Ins(1,4,5)P 3 ) [1] . Through a series of studies the authors have produced evidence for a messenger role of cADPR and importance of Ry in glucose-stimulated increase in [Ca 2+ ] i [3] . Okamoto et al's interest in the NAD metabolite cADPR appears to stem from their earlier works where they demonstrate a crucial role for the cellular level of NAD in mediating diverse processes such as beta cell damage and beta cell tumour formation [4] .
Background
Lee et al. [5] identified the structure of an active metabolite, i. e. cADPR responsible for the Ca 2+ -releasing effect of b -NAD + in sea urchin eggs. It has since been demonstrated that cADPR also releases Ca 2+ from intracellular non-mitochondrial stores in many mammalian cells [6] . These studies suggest that cADPR activates an intracellular Ca 2+ channel having the pharmacological properties of Ry [7] . Early reactions to the discovery of cADPR was that this molecule is the endogenous ligand for Ry just as Ins(1,4,5)P 3 is the natural ligand for its receptor [8] . The enzymatic mechanisms for synthesis and degradation of cADPR have been characterized and the enzymes are known to be present in many cells. Despite this remarkable progress, some uncomfortable controversies have emerged regarding the physiological role of cADPR and even its Ca 2+ -mobilizing effect. From this point of view, the case of the pancreatic beta cell is noteworthy because it was the first cell type where a physiological role for cADPR in mediating stimulus-secretion coupling was claimed [1] . In this commentary, we shall analyse the controversial aspects of cADPR in beta cells and attempt to identify possible reasons for such differences.
Does cADPR release Ca
2+ from intracellular stores in insulin-secreting cells?
The claim that cADPR and not Ins(1,4,5)P 3 releases Ca 2+ from intracellular stores in beta cells [1] -release by cADPR have not attempted to exactly duplicate the study of Takasawa et al. [1] . There seems, however, little incentive to do so. Such studies would require large numbers of islets which cannot be readily obtained. Moreover, the methods used in collection of large numbers of rat islets and preparation of microsomes from them, make it inevitable that significant contamination from alpha and delta cells, endothelial cells, fibroblasts, acinar cells and even lymph nodes, vessels and ducts may occur [13] . These latter cells may contain Ry in abundance (compared to low level of the receptor in beta cells) which may complicate interpretation of results obtained from islet microsome studies.
Other 
cADPR-metabolizing enzymes in beta cells
Beta cells express two bifunctional enzymes CD38 and bone marrow stromal antigen 1 (BST-1) involved in synthesis and degradation of cADPR [36] . CD38 catalyses at its extracellular domain the synthesis of cADPR from b -NAD + as well as hydrolysis of cADPR to ADP ribose. Transgenic mice, overexpressing CD38 in beta cells manifest increased insulin secretion in response to glucose [3] . This has been attributed to increased formation of cADPR by CD38 and consequent increased release of Ca 2+ from intracellular stores. CD38, however, appears to be involved in many physiological functions and other mechanisms by which it might affect secretion may need to be considered. For instance, CD38 can possibly act as an ADP-ribosylating enzyme and may induce insulin secretion by ADP-ribosylation of proteins including G-proteins [37, 38] . Whether in transgenic mice, CD38 overexpression may enhance insulin secretion by subtle effects on development and growth of beta cells also needs to be explored.
Difficulties in demonstrating Ca

2+ -release by cADPR in other cells
The controversy regarding the Ca 2+ -mobilizing effect of cADPR and its significance is not unique to beta cells. In the heart, it has been demonstrated that cADPR releases Ca 2+ from isolated sarcoplasmic reticulum vesicles and activates Ry incorporated in the planar lipid bilayer [28] . However, the results could not be reproduced by others [39, 40] . Liver cells do not seem to express mRNA of any of the known Rys, but cADPR has still been reported to release Ca 2+ from nuclear envelops of these cells [41] . On the other hand Lilly and Gollan [42] demonstrate that cADPR does not release Ca 2+ from hepatic microsomes. The list could be longer.
Conclusions
Dr. Okamoto's hypothesis that cADPR is a signalling molecule coupling glucose metabolism to increase in [Ca 2+ ] i in beta cells is interesting. The doubts derive from a failure by other investigators to reproduce their main finding, i. e. Ca 2+ -release by cADPR in beta cells. Even if it is accepted that cADPR might release Ca 2+ from intracellular stores in beta cells, the stand taken by Dr. Okamoto seems exaggerated when he regards this mechanism as one of primary importance. However, the intriguing observations made in studies with transgenic mice, may point to some modulatory role of cADPR in insulin secretion. Whether cADPR and CD38 may affect secretion in beta cells by mechanisms unrelated to the postulated Ca 
